Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Israel Comptroller To Propose End To Private Medicine, Raising Drug Issues

This article was originally published in PharmAsia News

Executive Summary

Israel’s state comptroller plans to propose an end to private medicine in the nation, leading to concerns about the accessibility of affordable drugs.

Israel’s state comptroller plans to propose an end to private medicine in the nation, leading to concerns about the accessibility of affordable drugs. Micha Lindenstrauss said he proposes abolishing the system or at least restricting it, but he has encountered backlash by Ministry of Health officials who question the proposal’s effect on insurance premiums and patient participation in medical procedures at private hospitals. Lindenstrauss said he was concerned about drugs being too cheap for many insurance policy-holders, leading to excessive treatments. (Click here for more)

“State Comptroller To Propose Curbing Private Medicine” Globes (Israel) (1/19/12)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC079330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel